Herpes Virus for Glioblastoma Post: What the Trial Found

An Instagram post from @selfcaresis, posted around September 29, 2026, summarizes a phase 1 trial of a genetically engineered herpes virus in 41 people with recurrent glioblastoma. It says the virus is designed to infect and kill tumor cells and draw T cells in, that stronger immune activity was linked with longer survival, and that this is "not a cure yet." The post cites no source.

View the original post

What the real trial is

This matches a first-in-human phase 1 trial of CAN-3110, an engineered herpes simplex virus (also called oncolytic HSV) injected into tumors. It was published in Nature in October 2023 (senior author E. Antonio Chiocca): "Clinical trial links oncolytic immunoactivation to survival in glioblastoma" (PubMed 37853118; ClinicalTrials.gov NCT03152318). So this is not a new 2026 result. We could not confirm whether the post presents it as new.

What's real

The post is largely accurate.

• 41 people with recurrent disease. The paper reports 41 patients with recurrent high-grade glioma. Of these, 32 had IDH-wildtype glioblastoma, the most common kind. The rest had two less common IDH-mutant types (4 and 5 patients). "41 people with recurrent glioblastoma" is a small simplification.
• A virus made to attack tumor cells. It is an engineered herpes virus designed to grow in tumor cells. After treatment, the researchers saw signs of immune activation in the tumors, including changes in T cells.
• Immune activity linked to survival. The authors report that survival was associated with changes in T cell counts and diversity and with immune-activation signatures in the tumor.
• No dose-limiting toxicities. The authors report none. Serious side effects still happened. Seizures that needed hospital care occurred in two patients, and the paper's supplementary data describe seizures that resolved with antiviral treatment. The paper reports no case of herpes brain infection (encephalitis) or meningitis.
• "Not a cure yet." Correct. The paper does not claim a cure. It describes one exceptional patient with a long response, not a typical outcome.

What's missing or wrong

Survival numbers. The post gives none. In the paper, median overall survival was 11.6 months for all 41 patients (95% CI 7.8 to 14.9) and 10.9 months for the 32 with IDH-wildtype glioblastoma (95% CI 6.9 to 14.4). The paper also found that people who already had antibodies to herpes (HSV1-positive) did better: median 14.2 months versus 7.8 months in those without them (P = 0.007). That difference was a main finding, and the post does not mention it.

"Linked" means association, not proof. There was no control group, and patients were not randomly assigned. The study was designed to test safety and dose. It cannot show that the virus lengthened survival. People with longer survival may have differed in other ways.

Small subgroups. Some subgroups are very small (4 and 5 people), so their numbers are unreliable.

What the evidence says

A phase 1 trial mainly asks whether a treatment is safe and what dose to use. It is a first step. Larger, controlled trials are needed to learn whether people live longer or feel better. See our guides to clinical trial phases and what clinical trial results mean. We did not open reports of later trials of CAN-3110, so we cannot say where further testing stands today.

Oncolytic viruses are not new as a concept. One, talimogene laherparepvec (Imlygic), is an approved modified herpes virus for some melanoma tumors. See Imlygic: what to expect. Its label says it has not been shown to improve overall survival. Glioblastoma itself is covered in our glioblastoma article.

What to do with this

If you or someone you love has recurrent glioblastoma, ask the neuro-oncology team whether a clinical trial fits your situation. Questions are listed in what to ask about brain tumor recurrence. Trials have entry rules, and not everyone qualifies. Do not try to obtain an experimental virus outside a trial.

If you have a fever of 100.4 F (38 C) or higher during cancer treatment, call your care team right away. For emergencies, call 911.

Sources

• Instagram post (@selfcaresis): instagram.com
• Ling AL, Solomon IH, and others, "Clinical trial links oncolytic immunoactivation to survival in glioblastoma," Nature 2023, PubMed record: pubmed.ncbi.nlm.nih.gov
• Same paper, full text in PubMed Central: pmc.ncbi.nlm.nih.gov

How this article was prepared

An AI-assisted editorial system helped prepare this page. It used the PubMed record and the open-access full text of the paper, which we opened on October 31, 2026. We read only part of the long full text. The journal page itself did not open for us. We could not view the Instagram post itself, so we rely on the caption as supplied to us. No named medical reviewer has reviewed it unless one is listed.

Cancer Explained is published by the National Cancer Information Foundation. It is not medical advice and does not suggest a test or treatment.

See an error, old source, or unclear wording? Tell us.